In fact, I have been watching IDIX and waiting for a good chance to get in. Their HepC drug is second after VRTX's. If I own both IDIX and VRTX and distribute my investment properly, it's a win-win regardless of the outcomes of VX-950. Futhermore, they also have HepB drugs with big hidden market potential.
BTW, your TA analysis posts were very helpful. The NASDAQ seems to have a very different story to tell. I am not any where near your TA level. It would be much appreciated if you could find some time to look at it. Thanks.